Despite significant advances in the treatment of hematologic cancers with BTK inhibitors (e.g., ibrutinib) and BCL-2 inhibitors (e.g., venetoclax), resistance and disease relapse remain major challenges (21). This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.